Lipella Pharmaceuticals Statistics Share Statistics Lipella Pharmaceuticals has 4.47M
shares outstanding. The number of shares has increased by -44.19%
in one year.
Shares Outstanding 4.47M Shares Change (YoY) -44.19% Shares Change (QoQ) 75.27% Owned by Institutions (%) n/a Shares Floating 4.18M Failed to Deliver (FTD) Shares 8,164 FTD / Avg. Volume 23.96%
Short Selling Information The latest short interest is 2.88K, so 0.06% of the outstanding
shares have been sold short.
Short Interest 2.88K Short % of Shares Out 0.06% Short % of Float 0.07% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.64 and the forward
PE ratio is -0.03.
Lipella Pharmaceuticals's PEG ratio is
0.03.
PE Ratio -0.64 Forward PE -0.03 PS Ratio 5.96 Forward PS 4.6 PB Ratio 1.67 P/FCF Ratio -0.81 PEG Ratio 0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Lipella Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.47,
with a Debt / Equity ratio of 0.02.
Current Ratio 3.47 Quick Ratio 3.47 Debt / Equity 0.02 Debt / EBITDA -0.01 Debt / FCF -0.01 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $107.27K Profits Per Employee $-1M Employee Count 5 Asset Turnover 0.2 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -83.91% in the
last 52 weeks. The beta is -0.09, so Lipella Pharmaceuticals's
price volatility has been lower than the market average.
Beta -0.09 52-Week Price Change -83.91% 50-Day Moving Average 1.4 200-Day Moving Average 2.46 Relative Strength Index (RSI) 26.62 Average Volume (20 Days) 34,067
Income Statement In the last 12 months, Lipella Pharmaceuticals had revenue of 536.36K
and earned -5.02M
in profits. Earnings per share was -4.79.
Revenue 536.36K Gross Profit -3.08M Operating Income -5.08M Net Income -5.02M EBITDA -5.01M EBIT -5.02M Earnings Per Share (EPS) -4.79
Full Income Statement Balance Sheet The company has 2.18M in cash and 47.6K in
debt, giving a net cash position of 2.14M.
Cash & Cash Equivalents 2.18M Total Debt 47.6K Net Cash 2.14M Retained Earnings -15.34M Total Assets 4.86M Working Capital 4.05M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -3.95M
and capital expenditures 0, giving a free cash flow of -3.95M.
Operating Cash Flow -3.95M Capital Expenditures n/a Free Cash Flow -3.95M FCF Per Share -3.77
Full Cash Flow Statement Margins Gross margin is -573.65%, with operating and profit margins of -947.23% and -935.25%.
Gross Margin -573.65% Operating Margin -947.23% Pretax Margin -935.25% Profit Margin -935.25% EBITDA Margin -934.71% EBIT Margin -947.23% FCF Margin -736.59%
Dividends & Yields LIPO does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for LIPO is $16,
which is 2566.7% higher than the current price. The consensus rating is "Buy".
Price Target $16 Price Target Difference 2566.7% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 8, 2024. It was a
backward
split with a ratio of 1:8.
Last Split Date Nov 8, 2024 Split Type backward Split Ratio 1:8
Scores Altman Z-Score -865.64 Piotroski F-Score 2
